Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03897127 |
|
Recruitment Status :
Recruiting
First Posted : April 1, 2019
Last Update Posted : November 18, 2023
|
Sponsor:
University of Ulm
Collaborator:
Jazz Pharmaceuticals
Information provided by (Responsible Party):
Verena Gaidzik, University of Ulm
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2024 |
| Estimated Study Completion Date : | March 2024 |